SCHEMBL5545382

SCHEMBL5545382

Cc1cnc2cccc([O])c2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.50
HTT P42858 3/20 0.38
KMT2A Q03164 3/20 0.38
MAPT P10636 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HPGD P15428 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
KDM4E B2RXH2 3/20 0.37
PSMD14 O00487 1/20 0.37
COPS5 Q92905 1/20 0.37
CCR1 P32246 1/20 0.36
CCR5 P51681 1/20 0.36
CCR8 P51685 1/20 0.36
PARP1 P09874 2/20 0.36
GPR3 P46089 1/20 0.35
PDK2 Q15119 1/20 0.35
PDK4 Q16654 1/20 0.35
MEN1 O00255 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2633153 0.80 CYP1A2 (0.53) CYP1A2KDM4EPSMD14COPS5CCR1
SCHEMBL30666632 0.80 CYP1A2 (0.53) CYP1A2KDM4EPSMD14COPS5CCR1
SCHEMBL11893012 0.78 CYP1A2 (0.47) CYP1A2HTTKMT2AMAPTALDH1A1
SCHEMBL18905193 0.78 CYP1A2 (0.47) CYP1A2HTTKMT2AMAPTALDH1A1
SCHEMBL14405531 0.77 CYP1A2 (0.50) CYP1A2KMT2AMAPTKDM4EPSMD14
SCHEMBL21893491 0.77 PDGFRB (0.51) CYP1A2HTTALDH1A1HPGDNPSR1
SCHEMBL29923227 0.77 CYP1A2 (0.50) CYP1A2HTTALDH1A1HPGDNPSR1
SCHEMBL4764348 0.77 KDM4E (0.55) CYP1A2KMT2AMAPTALDH1A1HPGD
SCHEMBL5215594 0.77 KDM4E (0.53) CYP1A2HTTKMT2AALDH1A1HPGD
SCHEMBL6425923 0.77 CYP1A2 (0.50) CYP1A2HTTALDH1A1HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP1A2 659/4885HTT 4644/4885KMT2A 4267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.